Opinion|Videos|July 1, 2024
Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer
A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For a patient whose cancer has progressed, do you obtain a new biopsy or go back to the original sample? Why?
- What biomarkers do you test for in advanced-stage breast cancer and when? Is there a need for NGS testing before first-line metastatic disease? (eg, BRCA, PIK3CA, PD-L1, NTRK, MSI-H/dMMR, TMB-H)
Advertisement
Related to this article
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5